先前我们已经描述了将吲哚啉-2-一-5-羧酰胺确定为有效的PAK4抑制剂。这项研究通过对先导化合物2和3进行一些修饰,扩展了我们原始系列的构效关系。在生化和细胞分析中设计,合成和评估了一系列新型衍生物。该系列中的大多数显示出针对A549和HCT116细胞的纳摩尔生化活性和有效的抗增殖活性。代表性化合物10a表现出优异的酶抑制作用(PAK4 IC 50 = 25 nM)和细胞效价(A549 IC 50 = 0.58μM,HCT116 IC 50 = 0.095μM)。化合物的X射线结构获得与PAK4结合的10a。晶体学分析证实了分子模型的预测,并有助于改进SAR结果。另外,化合物10a显示出集中的多靶点激酶抑制作用,良好的计算药物相似性。化合物10a的进一步分析表明,它对人细胞色素P450的各种同工型均显示出弱的抑制活性。
An Efficient Preparation of 2-Imidazolines and Imidazoles from Aldehydes with Molecular Iodine and (Diacetoxyiodo)benzene
作者:Hideo Togo、Midori Ishihara
DOI:10.1055/s-2005-923604
日期:——
2-Imidazolines were easily prepared in quite good yields from the reaction of aldehydes and ethylenediamine with molecular iodine in the presence of potassium carbonate. Moreover, 2-imidazolines obtained were smoothly oxidized to the corresponding imidazoles in good yields using (diacetoxyiodo)benzene at room temperature.
2,5-DIAZACYCLOPENTADIENYUDENE: A STANDARD CARBENE OR A HIGHLY REACTIVE DIRADICAL ?
作者:Núria Bru、Jaume Vilarrasa
DOI:10.1246/cl.1980.1489
日期:1980.12.5
2,5-Diazacyclopentadienylidene (2H-imidazolylidene), generated either by photolysis or thermolysis from 2-diazo-2H-imidazole, reacts with benzene derivatives to give mainly a mixture of o-, m-, and p-substituted 2-phenylimidazoles. The carbene shows a strong diradical character, in sharp contrast with the well-known behavior of cyclopentadienylidene.
Triazine derivatives as inhibitors of phosphodiesterases
申请人:Stange Hans
公开号:US20100120762A1
公开(公告)日:2010-05-13
The invention relates to triazine derivatives of formula (I):
which are inhibitors of phosphodiesterase 2 or 10, useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type 2 diabetes, metabolic syndrome, glucose intolerance, and pain.
[EN] IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE OU D'IMIDAZOPYRIMIDINE EN TANT QU'INHIBITEURS DE PHOSPHODIESTÉRASE 10A
申请人:HOFFMANN LA ROCHE
公开号:WO2011036127A1
公开(公告)日:2011-03-31
The invention is concerned with novel imidazopyridine derivatives of formula (I) wherein R1, R2, R3, R4, R5 and A are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.
[EN] BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS DE BENZOXAZÉPINE INHIBITEURS DE PI3K ET LEURS PROCÉDÉS D'UTILISATION
申请人:HOFFMANN LA ROCHE
公开号:WO2011036280A1
公开(公告)日:2011-03-31
The invention relates to benzoxazepin compounds of Formula (I) including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring which compounds have anti-cancer activity, and more specifically, inhibit PI3 kinase activity.